Clinical Trial Update: A Study to Assess the Efficacy and Safety of Lenalidomide in Combination With Cetuximab in Pre-treated Patients With KRAS Mutant Colorectal Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating lenalidomide plus cetuximab in pre-treated KRAS-mutant colorectal cancer was terminated, with results posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Cetuximab (cetuximab)
• Lenalidomide (lenalidomide)

Snippet

Sponsor: Celgene Corporation | Conditions: Colorectal Cancer | Phase 2 | Status: TERMINATED | Results posted: 2013-05-21